HealthMore in Health →
FDA Seeks More Data on Lilly’s Foundayo After Flagging Possible Safety Risks
The FDA has asked Eli Lilly for additional data on its obesity pill Foundayo as the agency evaluates potential risks related to major cardiovascular events and liver damage.
Key Takeaways
- The FDA is asking Eli Lilly for additional data on Foundayo.
- The agency is evaluating potential risks tied to major cardiovascular events and liver damage.
DE
DT Editorial AI··via endpoints.news
